Expression of VEGF and Its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2381-2390

  Kopparapu, Pradeep Kumar ^a   Boorjian, Stephen A ^b   Robinson, Brian D ^c   Downes, Martin ^c   Gudas, Lorraine J ^d   Mongan, Nigel P ^c   Persson, Jenny L ^a  

^a LUND UNIVERSITY   (Sweden)

^b MAYO CLINIC   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Angiogenesis; Bladder cancer; Disease recurrence; VEGF; VEGFR1; VEGFR2

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; MESSENGER RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUCOSA; CANCER RECURRENCE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR INVASION; ANGIOGENESIS; BLADDER TUMOR; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RECURRENT DISEASE; STAINING; VEGFR1; VEGFR2;

ANGIOGENESIS; BLADDER CANCER; DISEASE RECURRENCE; VEGF; VEGFR1; VEGFR2;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; STAINING AND LABELING; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MLCS; MLOWN;

EID: 84881348980     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cheung G, Sahai A, Billlia M, Dasgupta P and Khan MS: Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 11: 13, 2013.
2. Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB and Guzzo TJ: Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int, Jan 29, 2013. Epub ahead of print.
3. Van Tilborg AA, Bangma CH and Zwarthoff EC: Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 16: 23-30, 2009.
4. Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E and Bittard H: Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep 21: 1495-1504, 2009.
5. Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin 60: 244-272, 2010.
6. Proctor I, Stoeber K and Williams GH: Biomarkers in bladder cancer. Histopathology 57: 1-13, 2010.
7. Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, Davis ID and Stockler MR: Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: A systematic review with meta-Analysis. BJU Int, Dec. 17, 2012. Epub ahead of print.
8. Campbell SC, Volpert OV, Ivanovich M and Bouck NP: Molecular mediators of angiogenesis in bladder cancer. Cancer Res 58: 1298-1304, 1998.
9. Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F and Kandemir B: Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205: 854-857, 2009.
10. Urquidi V, Goodison S, Kim J, Chang M, Dai Y and Rosser CJ: Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 79: 1185 e1181-1186, 2012.
11. Black PC and Dinney CP: Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26: 623-634, 2007.
12. Verma A, Degrado J, Hittelman AB, Wheeler MA, Kaimakliotis HZ and Weiss RM: Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. BJU Int 107: 1154-1161, 2011.
13. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R and Lotan Y: Association of angiogenesis-related markers with bladder cancer outcomes and other molecular markers. J Urol 183: 1744-1750, 2010.
14. Elfiky AA and Rosenberg JE: Targeting angiogenesis in bladder cancer. Curr Oncol Rep 11: 244-249, 2009.
15. Pinto A, Redondo A, Zamora P, Castelo B and Espinosa E: Angiogenesis as a therapeutic target in urothelial carcinoma. Anticancer Drugs 21: 890-896, 2010.
16. Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D, Kogevinas M, Dosemeci M, Figueroa J, Chatterjee N, Tardon A, Serra C, Carrato A, Garcia-Closas R, Murta-Nascimento C, Rothman N and Chanock SJ: Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3: e29, 2007.
17. Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, Kraemer K, Fuessel S, Toma M, Schwenzer B, Meye A, Grimm MO, Hakenberg OW, Jocham D and Wirth MP: Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 32: 1049-1056, 2008.
18. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S and Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all trans-retinoic acid. Oncogene 24: 8025-8037, 2005.
19. Wey JS, Stoeltzing O and Ellis LM: Vascular endothelial growth factor receptors: Expression and function in solid tumors. Clin Adv Hematol Oncol 2: 37-45, 2004.
20. Hameed DA and el-Metwally TH: The effectiveness of retinoic acid treatment in bladder cancer: Impact on recurrence, survival and TGFα and VEGF as end-point biomarkers. Cancer Biol Ther 7: 92-100, 2008.
21. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP and Gill PS: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175: 1245-1252, 2006.
22. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T and Kanayama HO: Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 83: 98-106, 2009.
23. Videira PA, Piteira AR, Cabral MG, Martins C, Correia M, Severino P, Gouveia H, Carrascal M, Almeida JF, Trindade H and Santos LL: Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines. Urol Int 86: 95-101, 2011.
24. Goodison S, Chang M, Dai Y, Urquidi V and Rosser CJ: A multi-Analyte assay for the non-invasive detection of bladder cancer. PLoS One 7: e47469, 2012.
25. Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J and Boorjian SA: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is up-regulated in a subset of human bladder cancers. BJU Int 108: E84-90, 2011.
26. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
27. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K and Orntoft TF: Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048, 2004.
28. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vogeli TA and Grimm MO: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: Use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10: 3410-3421, 2004.
29. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P and Waldman FM: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11: 4044-4055, 2005.
30. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ and Mongan NP: Role of androgen receptor and associated lysine-demethylase co-regulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 50: 931-944, 2011.
31. Larsson R, Mongan NP, Johansson M, Shcherbina L, Abrahamsson PA, Gudas LJ, Sterner O and Persson JL: Clinical trial update and novel therapeutic approaches for metastatic prostate cancer. Curr Med Chem 18: 4440-4453, 2011.
32. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH and Worzel WP: The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6: 159, 2006.
33. O'Brien T, Cranston D, Fuggle S, Bicknell R and Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55: 510-513, 1995.